{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:39:47Z","timestamp":1792719587287,"version":"4.5.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"vor","delay-in-days":87,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Discov."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Bladder cancer (BC) remains a clinically challenging urothelial malignancy, largely because a substantial proportion of patients have no effective treatment options. Epidemiological studies have shown that metformin can improve the survival rate of cancer patients. However, its clinical application is limited by the requirement of high concentrations to exert antitumor effects. To overcome this limitation, we modified and optimized the biguanide structure using the intermediate derivatization methods and obtained a novel biguanide derivative\n                    <jats:bold>4C<\/jats:bold>\n                    . Our study revealed that\n                    <jats:bold>4C<\/jats:bold>\n                    suppressed the expression of sterol regulatory element-binding protein 1 (SREBP1), thereby inhibiting the transcription of fatty acid synthase (FASN) and downregulating its protein expression. Concurrently,\n                    <jats:bold>4C<\/jats:bold>\n                    inhibited the expression of ferroptosis-related regulatory proteins NRF2, SLC7A11, and GPX4, induced ferroptosis and effectively suppressed the proliferation and migration of BC cells. Notably, this inhibitory effect was markedly attenuated by the ferroptosis-specific inhibitor ferrostatin-1. Furthermore, we found that inducing ferroptosis was an effective approach to sensitize BRCA1\/2 wild-type BC cells to poly (ADP-ribose) polymerase (PARP) inhibitors. Accordingly,\n                    <jats:bold>4C<\/jats:bold>\n                    enhanced the sensitivity of BC cells to the PARP inhibitor talazoparib by reducing glutathione (GSH) levels, promoting reactive oxygen species (ROS) accumulation, and increasing malondialdehyde (MDA) levels. However, in the presence of ferrostatin-1, the sensitizing effect of 4C on talazoparib was reversed. In conclusion, this study demonstrated that the combination of\n                    <jats:bold>4C<\/jats:bold>\n                    and talazoparib induces ferroptosis via the SREBP1\/FASN axis, providing a promising novel combination therapeutic strategy for the treatment of BC.\n                  <\/jats:p>","DOI":"10.1038\/s41420-026-03270-0","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T11:09:52Z","timestamp":1785236992000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The novel biguanide derivative 4C synergizes with talazoparib by inducing ferroptosis via the SREBP1\/FASN\/ SLC7A11\/GPX4 axis in bladder cancer"],"prefix":"10.1038","volume":"12","author":[{"given":"Jia","family":"Yao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weifan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cangcang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1952-7227","authenticated-orcid":false,"given":"Xiaoping","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"key":"3270_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.217676","volume":"620","author":"ZD Shi","year":"2025","unstructured":"Shi ZD, Liu Y, Tao ZQ, Chao L, Zhang ZG, Sun F, et al. Apigenin inhibits recurrent bladder cancer progression by targeting VEGF-\u03b2. Cancer Lett. 2025;620:217676.","journal-title":"Cancer Lett"},{"key":"3270_CR2","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.7150\/ijbs.107632","volume":"21","author":"D Li","year":"2025","unstructured":"Li D, Su H, Deng X, Huang Y, Wang Z, Zhang J, et al. DARS2 promotes bladder cancer progression by enhancing PINK1-mediated mitophagy. Int J Biol Sci. 2025;21:1530\u201344.","journal-title":"Int J Biol Sci"},{"key":"3270_CR3","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","volume":"81","author":"M Babjuk","year":"2022","unstructured":"Babjuk M, Burger M, Capoun O, Cohen D, Comp\u00e9rat EM, Dominguez Escrig JL, et al. European Association of Urology Guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ). Eur Urol. 2022;81:75\u201394.","journal-title":"Eur Urol"},{"key":"3270_CR4","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025;75:10\u201345.","journal-title":"CA Cancer J Clin"},{"key":"3270_CR5","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.euf.2020.02.012","volume":"6","author":"S Daneshmand","year":"2020","unstructured":"Daneshmand S. Bladder cancer: advances and innovations. Eur Urol Focus. 2020;6:613\u20134.","journal-title":"Eur Urol Focus"},{"key":"3270_CR6","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1001\/jama.2020.17598","volume":"324","author":"AT Lenis","year":"2020","unstructured":"Lenis AT, Lec PM, Chamie K, Mshs MD. Bladder cancer: a review. JAMA. 2020;324:1980\u201391.","journal-title":"JAMA"},{"key":"3270_CR7","doi-asserted-by":"publisher","first-page":"6720.","DOI":"10.3390\/molecules28186720","volume":"28","author":"X Zhang","year":"2023","unstructured":"Zhang X, Hu X, Xie Y, Xie L, Chen X, Peng M, et al. Metformin-loaded chitosan hydrogels suppress bladder tumor growth in an orthotopic mouse model via intravesical administration. Molecules. 2023;28:6720.","journal-title":"Molecules"},{"key":"3270_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2024.101059","volume":"73","author":"F Li","year":"2024","unstructured":"Li F, Zhang H, Huang Y, Li D, Zheng Z, Xie K, et al. Single-cell transcriptome analysis reveals the association between histone lactylation and cisplatin resistance in bladder cancer. Drug Resist Updat. 2024;73:101059.","journal-title":"Drug Resist Updat"},{"key":"3270_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202309215","volume":"20","author":"S Lu","year":"2024","unstructured":"Lu S, Tian H, Li B, Li L, Jiang H, Gao Y, et al. An ellagic acid coordinated copper-based nanoplatform for efficiently overcoming cancer chemoresistance by cuproptosis and synergistic inhibition of cancer cell stemness. Small. 2024;20:e2309215.","journal-title":"Small"},{"key":"3270_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2022.155223","volume":"133","author":"CR Triggle","year":"2022","unstructured":"Triggle CR, Mohammed I, Bshesh K, Marei I, Ye K, Ding H, et al. Metformin: Is it a drug for all reasons and diseases? Metabolism. 2022;133:155223.","journal-title":"Metabolism"},{"key":"3270_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.865988","volume":"13","author":"CQ Liu","year":"2022","unstructured":"Liu CQ, Sun JX, Xu JZ, Qian XY, Hong SY, Xu MY, et al. Metformin use on incidence and oncologic outcomes of bladder cancer patients with T2DM: an updated meta-analysis. Front Pharm. 2022;13:865988.","journal-title":"Front Pharm"},{"key":"3270_CR12","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1186\/s13046-019-1346-1","volume":"38","author":"Y Wu","year":"2019","unstructured":"Wu Y, Zheng Q, Li Y, Wang G, Gao S, Zhang X, et al. Metformin targets a YAP1-TEAD4 complex via AMPK\u03b1 to regulate CCNE1\/2 in bladder cancer cells. J Exp Clin Cancer Res. 2019;38:376.","journal-title":"J Exp Clin Cancer Res"},{"key":"3270_CR13","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1152\/jn.00417.2020","volume":"125","author":"Z Liang","year":"2021","unstructured":"Liang Z, Zhang T, Zhan T, Cheng G, Zhang W, Jia H, et al. Metformin alleviates cisplatin-induced ototoxicity by autophagy induction possibly via the AMPK\/FOXO3a pathway. J Neurophysiol. 2021;125:1202\u201312.","journal-title":"J Neurophysiol"},{"key":"3270_CR14","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.neo.2019.03.007","volume":"21","author":"O Maehara","year":"2019","unstructured":"Maehara O, Ohnishi S, Asano A, Suda G, Natsuizaka M, Nakagawa K, et al. Metformin regulates the expression of CD133 through the AMPK-CEBP\u03b2 pathway in hepatocellular carcinoma cell lines. Neoplasia. 2019;21:545\u201356.","journal-title":"Neoplasia"},{"key":"3270_CR15","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/s41392-021-00493-8","volume":"6","author":"J Deng","year":"2021","unstructured":"Deng J, Peng M, Zhou S, Xiao D, Hu X, Xu S, et al. Metformin targets Clusterin to control lipogenesis and inhibit the growth of bladder cancer cells through SREBP-1c\/FASN axis. Signal Transduct Target Ther. 2021;6:98.","journal-title":"Signal Transduct Target Ther"},{"key":"3270_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.236","volume":"4","author":"D Xiao","year":"2023","unstructured":"Xiao D, Xu S, Zhou X, Li D, Peng M, Chu X, et al. Synergistic augmentation of osimertinib-induced autophagic death by proguanil or rapamycin in bladder cancer. MedComm. 2023;4:e236.","journal-title":"MedComm"},{"key":"3270_CR17","doi-asserted-by":"publisher","first-page":"5622","DOI":"10.1158\/1078-0432.CCR-18-0420","volume":"24","author":"Q Liu","year":"2018","unstructured":"Liu Q, Tong D, Liu G, Gao J, Wang LA, Xu J, et al. Metformin inhibits prostate cancer progression by targeting tumor-associated inflammatory infiltration. Clin Cancer Res. 2018;24:5622\u201334.","journal-title":"Clin Cancer Res"},{"key":"3270_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2025.102534","volume":"61","author":"Y Lai","year":"2025","unstructured":"Lai Y, Peng Z, He Z, Lu Z, Yan S, Nie Q, et al. Dioscin initiates dual roles in bladder cancer progression via miR-195-5p\/FASN\/SLC3A2 axis-mediated cell death mechanisms. Transl Oncol. 2025;61:102534.","journal-title":"Transl Oncol"},{"key":"3270_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-09376-9","volume":"22","author":"S Bhattacharjee","year":"2022","unstructured":"Bhattacharjee S, Sullivan MJ, Wynn RR, Demagall A, Hendrix AS, Sindhwani P, et al. PARP inhibitors chemopotentiate and synergize with cisplatin to inhibit bladder cancer cell survival and tumor growth. BMC Cancer. 2022;22:312.","journal-title":"BMC Cancer"},{"key":"3270_CR20","doi-asserted-by":"publisher","first-page":"5775.","DOI":"10.3390\/molecules26195775","volume":"26","author":"S Xu","year":"2021","unstructured":"Xu S, Cao Y, Luo Y, Xiao D, Wang W, Wang Z, et al. Synthesis, anti-proliferative evaluation and mechanism of 4-trifluoro methoxy proguanil derivatives with various carbon chain length. Molecules. 2021;26:5775.","journal-title":"Molecules"},{"key":"3270_CR21","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/s41580-024-00703-5","volume":"25","author":"SJ Dixon","year":"2024","unstructured":"Dixon SJ, Olzmann JA. The cell biology of ferroptosis. Nat Rev Mol Cell Biol. 2024;25:424\u201342.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3270_CR22","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.cell.2017.09.021","volume":"171","author":"BR Stockwell","year":"2017","unstructured":"Stockwell BR, Friedmann Angeli JP, Bayir H, Bush AI, Conrad M, Dixon SJ, et al. Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell. 2017;171:273\u201385.","journal-title":"Cell"},{"key":"3270_CR23","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.canlet.2016.07.035","volume":"381","author":"JL Roh","year":"2016","unstructured":"Roh JL, Kim EH, Jang HJ, Park JY, Shin D. Induction of ferroptotic cell death for overcoming cisplatin resistance of head and neck cancer. Cancer Lett. 2016;381:96\u2013103.","journal-title":"Cancer Lett"},{"key":"3270_CR24","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/nature24297","volume":"551","author":"MJ Hangauer","year":"2017","unstructured":"Hangauer MJ, Viswanathan VS, Ryan MJ, Bole D, Eaton JK, Matov A, et al. Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition. Nature. 2017;551:247\u201350.","journal-title":"Nature"},{"key":"3270_CR25","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41392-024-01769-5","volume":"9","author":"Q Zhou","year":"2024","unstructured":"Zhou Q, Meng Y, Li D, Yao L, Le J, Liu Y, et al. Ferroptosis in cancer: From molecular mechanisms to therapeutic strategies. Signal Transduct Target Ther. 2024;9:55.","journal-title":"Signal Transduct Target Ther"},{"key":"3270_CR26","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13045-019-0720-y","volume":"12","author":"Y Mou","year":"2019","unstructured":"Mou Y, Wang J, Wu J, He D, Zhang C, Duan C, et al. Ferroptosis, a new form of cell death: opportunities and challenges in cancer. J Hematol Oncol. 2019;12:34.","journal-title":"J Hematol Oncol"},{"key":"3270_CR27","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.ccell.2019.04.002","volume":"35","author":"B Hassannia","year":"2019","unstructured":"Hassannia B, Vandenabeele P, Vanden Berghe T. Targeting ferroptosis to iron out cancer. Cancer Cell. 2019;35:830\u201349.","journal-title":"Cancer Cell"},{"key":"3270_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.215919","volume":"550","author":"D Shen","year":"2022","unstructured":"Shen D, Luo J, Chen L, Ma W, Mao X, Zhang Y, et al. PARPi treatment enhances radiotherapy-induced ferroptosis and antitumor immune responses via the cGAS signaling pathway in colorectal cancer. Cancer Lett. 2022;550:215919.","journal-title":"Cancer Lett"},{"key":"3270_CR29","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1158\/2159-8290.CD-23-1220","volume":"14","author":"G Lei","year":"2024","unstructured":"Lei G, Mao C, Horbath AD, Yan Y, Cai S, Yao J, et al. BRCA1-mediated dual regulation of ferroptosis exposes a vulnerability to GPX4 and PARP co-inhibition in BRCA1-deficient cancers. Cancer Discov. 2024;14:1476\u201395.","journal-title":"Cancer Discov"},{"key":"3270_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01227-0","volume":"19","author":"H Li","year":"2020","unstructured":"Li H, Liu ZY, Wu N, Chen YC, Cheng Q, Wang J. PARP inhibitor resistance: the underlying mechanisms and clinical implications. Mol Cancer. 2020;19:107.","journal-title":"Mol Cancer"},{"key":"3270_CR31","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1158\/1541-7786.MCR-25-0268","volume":"23","author":"J Lesage","year":"2025","unstructured":"Lesage J, DiMauro A, Schab AM, Stidham S, Mullen MM, Fuh KC, et al. DDR2 confers ferroptosis resistance to cancer-associated fibroblasts and attenuates PARPi sensitivity of ovarian tumor cells. Mol Cancer Res. 2025;23:1012\u201324.","journal-title":"Mol Cancer Res"},{"key":"3270_CR32","doi-asserted-by":"publisher","first-page":"e455","DOI":"10.1002\/mco2.455","volume":"4","author":"M Peng","year":"2023","unstructured":"Peng M, Chu X, Peng Y, Li D, Zhang Z, Wang W, et al. Targeted therapies in bladder cancer: signaling pathways, applications, and challenges. MedComm. 2023;4:e455.","journal-title":"MedComm"},{"key":"3270_CR33","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.7150\/ijbs.105072","volume":"21","author":"D Xiao","year":"2025","unstructured":"Xiao D, Chu X, Wang W, Peng M, Lv Q, Xu C, et al. Inhibition of cyclin D1 by novel biguanide derivative YB-004 increases the sensitivity of bladder cancer to olaparib via causing G0 \/ G1 arrest. Int J Biol Sci. 2025;21:1984\u201398.","journal-title":"Int J Biol Sci"},{"key":"3270_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-04937-z","volume":"13","author":"D Xiao","year":"2022","unstructured":"Xiao D, Hu X, Peng M, Deng J, Zhou S, Xu S, et al. Inhibitory role of proguanil on the growth of bladder cancer via enhancing EGFR degradation and inhibiting its downstream signaling pathway to induce autophagy. Cell Death Dis. 2022;13:499.","journal-title":"Cell Death Dis"},{"key":"3270_CR35","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nchembio.2238","volume":"13","author":"VE Kagan","year":"2017","unstructured":"Kagan VE, Mao G, Qu F, Angeli JP, Doll S, Croix CS, et al. Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis. Nat Chem Biol. 2017;13:81\u201390.","journal-title":"Nat Chem Biol"},{"key":"3270_CR36","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.cell.2017.09.044","volume":"171","author":"SE Wenzel","year":"2017","unstructured":"Wenzel SE, Tyurina YY, Zhao J, St Croix CM, Dar HH, Mao G, et al. PEBP1 wardens ferroptosis by enabling lipoxygenase generation of lipid death signals. Cell. 2017;171:628\u201341. e26.","journal-title":"Cell"},{"key":"3270_CR37","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1073\/pnas.1808834116","volume":"116","author":"G Zadra","year":"2019","unstructured":"Zadra G, Ribeiro CF, Chetta P, Ho Y, Cacciatore S, Gao X, et al. Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer. Proc Natl Acad Sci USA. 2019;116:631\u201340.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3270_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2021.153806","volume":"93","author":"PF Hsieh","year":"2021","unstructured":"Hsieh PF, Jiang WP, Basavaraj P, Huang SY, Ruangsai P, Wu JB, et al. Cell suspension culture extract of Eriobotrya japonica attenuates growth and induces apoptosis in prostate cancer cells via targeting SREBP-1\/FASN-driven metabolism and AR. Phytomedicine. 2021;93:153806.","journal-title":"Phytomedicine"},{"key":"3270_CR39","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1186\/s13046-025-03548-8","volume":"44","author":"Z Qian","year":"2025","unstructured":"Qian Z, Jiang Y, Cai Y, Gao E, Wang C, Dong J, et al. FASN inhibits ferroptosis in breast cancer via USP5 palmitoylation-dependent regulation of GPX4 deubiquitination. J Exp Clin Cancer Res. 2025;44:289.","journal-title":"J Exp Clin Cancer Res"},{"key":"3270_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-025-07886-5","volume":"16","author":"T Zhao","year":"2025","unstructured":"Zhao T, Chen X, Wu J, Chen S, Gan Y, Liu C, et al. YY1-induced USP43 drives ferroptosis suppression by FASN stabilization and subsequent activation of SLC7A11 in ovarian cancer. Cell Death Dis. 2025;16:589.","journal-title":"Cell Death Dis"},{"key":"3270_CR41","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/nature03443","volume":"434","author":"HE Bryant","year":"2005","unstructured":"Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434:913\u20137.","journal-title":"Nature"},{"key":"3270_CR42","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41571-018-0114-z","volume":"16","author":"PG Pili\u00e9","year":"2019","unstructured":"Pili\u00e9 PG, Tang C, Mills GB, Yap TA. State-of-the-art strategies for targeting the DNA damage response in cancer. Nat Rev Clin Oncol. 2019;16:81\u2013104.","journal-title":"Nat Rev Clin Oncol"},{"key":"3270_CR43","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1158\/1078-0432.CCR-19-2933","volume":"26","author":"N Vidula","year":"2020","unstructured":"Vidula N, Rich TA, Sartor O, Yen J, Hardin A, Nance T, et al. Routine plasma-based genotyping to comprehensively detect germline, somatic, and reversion BRCA mutations among patients with advanced solid tumors. Clin Cancer Res. 2020;26:2546\u201355.","journal-title":"Clin Cancer Res"},{"key":"3270_CR44","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1200\/JCO.22.00405","volume":"41","author":"SJ Crabb","year":"2023","unstructured":"Crabb SJ, Hussain S, Soulis E, Hinsley S, Dempsey L, Trevethan A, et al. A randomized, double-blind, biomarker-selected, phase II clinical trial of maintenance poly ADP-ribose polymerase inhibition with rucaparib following chemotherapy for metastatic urothelial carcinoma. J Clin Oncol. 2023;41:54\u201364.","journal-title":"J Clin Oncol"},{"key":"3270_CR45","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.eururo.2022.09.025","volume":"83","author":"F Vignani","year":"2023","unstructured":"Vignani F, Tambaro R, De Giorgi U, Giannatempo P, Bimbatti D, Carella C, et al. Addition of niraparib to best supportive care as maintenance treatment in patients with advanced urothelial carcinoma whose disease did not progress after first-line platinum-based chemotherapy: the meet-URO12 randomized phase 2 trial. Eur Urol. 2023;83:82\u20139.","journal-title":"Eur Urol"},{"key":"3270_CR46","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1200\/JCO.22.00205","volume":"41","author":"JE Rosenberg","year":"2023","unstructured":"Rosenberg JE, Park SH, Kozlov V, Dao TV, Castellano D, Li JR, et al. Durvalumab plus olaparib in previously untreated, platinum-ineligible patients with metastatic urothelial carcinoma: a multicenter, randomized, phase II trial (BAYOU). J Clin Oncol. 2023;41:43\u201353.","journal-title":"J Clin Oncol"}],"container-title":["Cell Death Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41420-026-03270-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-026-03270-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-026-03270-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:30:41Z","timestamp":1792719041000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41420-026-03270-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3270"],"URL":"https:\/\/doi.org\/10.1038\/s41420-026-03270-0","relation":{},"ISSN":["2058-7716"],"issn-type":[{"value":"2058-7716","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,28]]},"assertion":[{"value":"31 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Animal experiments were approved by the Ethics Committee of Hunan Normal University (D2024044). All research protocols adhered to the Declaration of Helsinki.","order":2,"name":"Ethics","label":"Ethics statement","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"423"}}